Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Iptilimumab

Phase 3Monoclonal antibody

Iptilimumab is one of 13 small molecule programs targeting Brain Tumor. It is currently in Phase 3.

1

Indications

1

Total Trials

1

Active Trials

12

Competitors

Pipeline

Status by Indication[3][1]

Indication

Brain TumorRecruiting

Brain TumorPhase 3

Recruiting

Competition

Competitive Landscape

12 competitors in Brain Tumor

#DrugCompanyPhaseTrials

Keppra

Tecentriq

Keytruda

Libtayo

Opdivo

Bristol-Myers Squibb

Verzenio

Femara

Temodar

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Iptilimumab

Vectibix

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 3Recruiting

Brain Tumor

NCT05317858

Clinical

Trials by Indication[1]

Brain Tumor1 trial

A Randomized Pivotal Study Assessing the Safety and Efficacy of Targeted Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound During the Standard of Care Treatment of Brain Metastases of Non-small Cell Lung Cancer (NSCLC) Origin

Recruiting·IInSightec·Phase 3·NCT05317858·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Iptilimumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Iptilimumab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Iptilimumab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — InSightec company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 3[1]
Company: IInSightec

Related News